Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature 457, 532-533 (29 January 2009) | doi:10.1038/457532c; Published online 28 January 2009
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
- More Challenges
- Powered by:
nature jobs
Assoc. Scientific Manager / Scientific Manager - Biopharmaceutics
- Syngene International
- Bangalore, Karnataka 560099 India
Scientist (Bioinformatics)
- Polyclone Bioservices Pvt. Ltd
- Bangalore India
A medical view of potential adverse effects
Anjan Chatterjee1
- Department of Neurology and Center for Cognitive Neuroscience, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Email: anjan@mail.med.upenn.edu
Most seasoned physicians have had the sobering experience of prescribing medications that, despite good intentions, caused bad outcomes. They would call for louder notes of caution than those expressed in the Commentary by Henry Greely and colleagues (Nature 456, 702–705; 2008) when considering the safety of 'cognitive-enhancing' drugs such as Ritalin and Adderall.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Risks and benefits may turn out to be finely balancedNature Correspondence (29 Jan 2009)
Recall of learned information may rely on taking drug againNature Correspondence (29 Jan 2009)
Much ado about cognitive enhancementNature Correspondence (29 Jan 2009)
Patterns of drug use have varied throughout historyNature Correspondence (29 Jan 2009)
